Fund moves

Zevra Therapeutics (ZVRA): Rubric Capital Management LP exited its position 1.96M shares

Rubric Capital Management LP exited its position in Zevra Therapeutics, per its Q3 2025 13F.

1.96M
Prior-quarter shares · no longer reported
Holdings as of
Sep 30, 2025
Filed
Nov 14, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Sep 12, 2025Insider · 2 peopleInsiders: 2 purchases (~$183K)
  2. Nov 5, 2025Company filing · Form 8-K · ResultsReported its results

What came next

  1. Nov 20, 2025Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On November 20, 2025, R. LaDuane Clifton, the Chief Financial Officer and Treasurer and principal financial officer of Zevra Therapeutics, Inc. (the “Company”) notified the Company of his decision to resign from his position, effective December 31, 2025 (the “Separation Date”), in order to pursue other professional opportunities.”
  2. Nov 26, 2025Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On November 26, 2025, Wendy Dixon notified the board of directors (the “Board”) of Zevra Therapeutics, Inc. (the “Company”) that she was resigning from the Board and each committee of the Board on which she served, subject to the Board’s acceptance.”
  3. Dec 11, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On December 11, 2025, the board of directors (the “Board”) of Zevra Therapeutics, Inc. (the “Company”) appointed Timothy Sangiovanni, the Company’s current Senior Vice President, Finance and Corporate Controller and principal accounting officer, as interim principal financial officer, effective as of January 1, 2026.”
  4. Mar 4, 2026Company filing · Form 8-K · Results, Executive changeChanged a top executive or board member, and reported its results“On March 4, 2026, the Company appointed Justin Renz as Chief Financial Officer and Treasurer, effective March 9, 2026, and as principal financial officer, effective March 10, 2026.”
View the official recordSEC Form 13F-HR

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Zevra Therapeutics

For Zevra Therapeutics, OQRO holds 2 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ZVRA page.

How this filing works

Explore the data

Common questions

What does this filing report about Zevra Therapeutics (ZVRA) stock?

Rubric Capital Management LP exited its position in Zevra Therapeutics, per its Q3 2025 13F. Held the prior quarter, no longer listed per its Q3 2025 13F.

When did it happen, and when was it made public?

Holdings as of: Sep 30, 2025. Filed: Nov 14, 2025.

Is this a trade made on a known date?

No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

Where does this information come from?

From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Zevra Therapeutics recently?

For Zevra Therapeutics, OQRO holds 2 insider filings (SEC Form 4 or Form 144) dated in the last 90 days. They are listed on the ZVRA page.

Does this mean ZVRA stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Zevra Therapeutics

Everything OQRO holds on this company is on its ZVRA page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data